All In Biotech

Drug Trial Radar · NCT01363752

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

A Multicenter, Two Arm, Randomized, Open Label Clinical Study Investigating Renal Function in an Advagraf® Based Immunosuppressive Regimen With or Without Sirolimus in Kidney Transplant Patients

Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 853 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

853

Actual

Start

Mar 8, 2011

Primary completion

Sep 18, 2013

Study completion Sep 18, 2013

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effect of two anti-rejection therapy regimens on kidney function in kidney transplant recipients.

Conditions

  • Kidney Transplantation

Interventions

  • AdvagrafDrug

    oral

  • Mycophenolate MofetilDrug

    oral

  • SirolimusDrug

    oral

  • CorticosteroidsDrug

    i.v. and oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glomerular Filtration Rate (GFR) estimated by iohexol clearance at Week 52 post kidney transplantationTime frame: up to 1 year

Locations

58 sites in 17 countries. Site status is shown where the registry gives one.

  • 5042

    New Lambton, Australia

  • 5043

    Perth, Australia

  • 1141

    Innsbruck, Austria

  • 1142

    Linz, Austria

  • 1140

    Vienna, Austria

  • 3240

    Minsk, Belarus

  • 1241

    Leuven, Belgium

  • 1240

    Liège, Belgium

  • Site 1441

    Brno, Czechia

  • 1440

    Ostrava - Poruba, Czechia

  • 1752

    Amiens, France

  • 1740

    Brest, France

  • 1742

    Clermont-Ferrand, France

  • 1746

    Créteil, France

  • 1750

    Dijon, France

  • 1741

    Le Kremilin Bicetre Cedex, France

  • 1749

    Paris, France

  • 1751

    Toulouse, France

  • 1748

    Tours, France

  • 1745

    Vandœuvre-lès-Nancy, France

  • 1541

    Bochum, Germany

  • 1542

    Erlangen, Germany

  • 1543

    Essen, Germany

  • 1544

    Frankfurt, Germany

  • 1545

    Hannoversch Münden, Germany

  • 1540

    Hanover, Germany

  • 1546

    Heidelberg, Germany

  • 1547

    Kiel, Germany

  • 1548

    Leipzig, Germany

  • 1549

    München, Germany

  • 1550

    Münster, Germany

  • 5441

    Hong Kong, Hong Kong

  • 1940

    Budapest, Hungary

  • 2144

    Palermo, Italy

  • 2143

    Roma, Italy

  • 2140

    Siena, Italy

  • 2440

    Maastricht, Netherlands

  • 2643

    Katowice, Poland

  • 2640

    Lodz, Poland

  • 2641

    Poznan, Poland

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.